logo
Plus   Neg
Share
Email

AstraZeneca: Calquence Trial In Chronic Lymphocytic Leukaemia Met Primary Goal

British drug major AstraZeneca Plc (AZN.L,AZN) announced Tuesday that the Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia or CLL met primary endpoint.

The positive results showed a statistically-significant and clinically-meaningful improvement in progression-free survival with Calquence monotherapy compared to a combination regimen of rituximab plus physician's choice of idelalisib or bendamustine.

The safety and tolerability of Calquence was consistent with the known profile, the company noted.

According to the company, Calquence is the first Bruton tyrosine kinase or BTK inhibitor to show benefit in a Phase III trial as a monotherapy compared to current standard-of-care combinations used in relapsed or refractory CLL.

ASCEND is the first of two Phase III CLL trials expected to read out in 2019. The second is ELEVATE-TN in treatment-naïve, front-line CLL.

Calquence is currently approved for the treatment of adults with relapsed or refractory mantle cell lymphoma or MCL in the US, Brazil, the UAE, and Qatar. It is being developed for the treatment of CLL and other blood cancers.

AstraZeneca and its haematology research and development arm Acerta Pharma are currently evaluating Calquence in 26 clinical trials.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Auto giant General Motors' (GM) Chevrolet unveiled its new stunning Corvette Stingray 2020. Stingray 2020, the eighth generation of the Chevrolet Corvette, has received the biggest change since its initial launch in 1953. The new 2020 Corvette is a mid-engine vehicle, which is its engine is behind... Amazon.com's Prime Day has brought a smile to the face of some photographers who may have grabbed their best deals of their lives. The e-commerce giant accidentally discounted a wide range of premium camera gear for Prime Day earlier this week, which may have proved costly for it. Thanks to a pricing error, some lucky customers were able to buy premium camera gear bundles for below $100. Women's clothing chain Dress Barn Inc. said it started store-closing or inventory clearance event sales at the 53 stores it plans to close by the end of August. The company expects to close all its stories by end of 2019. It also released a list of the nine stores closing in July and the stores closing in August. Dressbarn has hired Gordon Brothers Retail Partners to help with the store closures.
Follow RTT